Impact of Dose Reduction of Afatinib Used in Patients With Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

• Main Authors: Ziyu Wang (Author), Xin Du (Author), Ken Chen (Author), Shanshan Li (Author), Zhiheng Yu (Author), Ziyang Wu (Author), Li Yang (Author), Dingding Chen (Author), Wei Liu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background and Aim: As one of the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, afatinib brings survival benefits to patients with common and rare EGFR mutations. This study aimed to compare the effectiveness and safety of 30 and 40 mg of afatinib in patients...